{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:37:40Z","timestamp":1765438660903,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bcmd.2020.102481","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T21:21:47Z","timestamp":1595539307000},"page":"102481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Potential \u2018significance\u2019 of monoclonal gammopathy of \u2018undetermined significance\u2019 during COVID-19 pandemic"],"prefix":"10.1016","volume":"85","author":[{"given":"Ankur","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2020.102481_bb0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcmd.2020.102481_bb0010","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European myeloma network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2020.102481_bb0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2020.102481_bb0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fimmu.2014.00257","article-title":"Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"5","author":"Tete","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4683","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2020.102481_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16906","article-title":"A case series of MGUS and COVID-19","author":"Gonzalez-Lugo","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0035","article-title":"COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers","author":"Hultcrantz","year":"2020","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.bcmd.2020.102481_bb0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16874","article-title":"Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy","author":"Cook","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0050","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2020.102481_bb0055","article-title":"Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bcmd.2020.102481_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.7869","article-title":"COVID-19 and Postinfection immunity: limited evidence, many remaining questions","author":"Kirkcaldy","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bcmd.2020.102481_bb0065","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/CM9.0000000000000774","article-title":"Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients","volume":"133","author":"Ling","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bcmd.2020.102481_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","author":"Levi","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bcmd.2020.102481_bb0075","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2007-976169","article-title":"Hemostatic dysfunction in paraproteinemias and amyloidosis","volume":"33","author":"Zangari","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2020.102481_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.bcmd.2020.102481_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16927","article-title":"Anticoagulation with Argatroban in patients with acute antithrombin deficiency in severe COVID \u221219","author":"Arachchillage","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0090","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and management of monoclonal gammopathy of renal significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bcmd.2020.102481_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16898","article-title":"Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic","author":"Kastritis","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/ane.13266","article-title":"Neurological manifestations of COVID-19: a systematic review and current update","volume":"142","author":"Whittaker","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bcmd.2020.102481_bb0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(20)30109-5","article-title":"Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2 infection: causality or coincidence?","volume":"19","author":"Zhao","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/ejhf.1828","article-title":"Myocardial localization of coronavirus in COVID-19 cardiogenic shock","volume":"22","author":"Tavazzi","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bcmd.2020.102481_bb0115","doi-asserted-by":"crossref","unstructured":"Jain A, Ramasamy K. Time to redefine risk-stratification and response criteria in immunoglobulin light chain amyloidosis?. Clin Lymphoma Myeloma Leuk. 2020. DOI:https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.clml.2020.05.025.","DOI":"10.1016\/j.clml.2020.05.025"},{"key":"10.1016\/j.bcmd.2020.102481_bb0120","first-page":"1","article-title":"Multiple myeloma in the time of COVID-19","author":"Al Saleh","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0125","article-title":"Hydroxychloroquine or Chloroquine for treatment or prophylaxis of COVID-19: a living systematic review","author":"Hernandez","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2020.102481_bb0130","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcmd.2020.102481_bb0135","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2020.102481_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcmd.2020.102481_bb0145","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","author":"Noonan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2020.102481_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.03.010","article-title":"Evolving role of Daratumumab: from backbencher to frontline agent","author":"Jain","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bcmd.2020.102481_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16815","article-title":"COVID-19 and myeloma: what are the implications for now and in the future?","author":"Freeman","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0160","unstructured":"COVID-19 and indolent lymphomas - Hematology.org. https:\/\/www.hematology.org\/covid-19\/covid-19-and-indolent-lymphomas. Accessed on 14 Apr 2020."},{"issue":"10236","key":"10.1016\/j.bcmd.2020.102481_bb0165","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.bcmd.2020.102481_bb0170","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2019-127023","article-title":"Upfront Ixazomib plus dexamethasone induce promptly hematological response in patients with light-chain amyloidosis","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2020.102481_bb0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2020.102481_bb0180","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bcmd.2020.102481_bb0185","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2020.102481_bb0190","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0195","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/acscentsci.0c00501","article-title":"Assay techniques and test development for COVID-19 diagnosis","volume":"6","author":"Carter","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bcmd.2020.102481_bb0200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.it.2020.04.001","article-title":"Improving vaccine-induced immunity: can baseline predict outcome?","volume":"41","author":"Tsang","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bcmd.2020.102481_bb0205","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/1547691X.2010.523881","article-title":"Human lymphocyte activation assay: an in vitro method for predictive immunotoxicity testing","volume":"7","author":"Collinge","year":"2010","journal-title":"J. Immunotoxicol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979620303867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979620303867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:35:34Z","timestamp":1761050134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979620303867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":41,"alternative-id":["S1079979620303867"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102481","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential \u2018significance\u2019 of monoclonal gammopathy of \u2018undetermined significance\u2019 during COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2020.102481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102481"}}